Immunophotonics, Inc.
Edit

Immunophotonics, Inc.

http://www.immunophotonics.com/
Last activity: 13.09.2024
Active
Categories: BioTechDrugHealthTechITLocal
INTERVENTIONAL IMMUNO-ONCOLOGY
Mentions
20
Location: United States, Missouri, Saint Louis
Total raised: $23.9M

Investors 7

Funding Rounds 2

DateSeriesAmountInvestors
25.10.2022Grant$2.5M-
06.04.2022-$21.4M-

Mentions in press and media 20

DateTitleDescription
13.09.2024Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3ST. LOUIS, MO, UNITED STATES, September 13, 2024 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biopharma company developing novel immune-stimulating drugs to augment routine tumor destruction techniques – such as tumor ablat...
15.08.2024Immunophotonics Announces 1st Patient Dosed in a Randomized Phase 2 Study at the University of LouisvilleSAINT LOUIS, MISSOURI, USA, August 15, 2024 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, in collaboration with Dr. Robert CG Martin ...
27.02.2024AngioDynamics and Immunophotonics Announces Partnership to Explore the Power of ImmunotherapyLATHAM, NEW YORK, February 27, 2024 /EINPresswire.com/ -- AngioDynamics, Inc. (NASDAQ: ANGO), a global provider of medical devices, and Immunophotonics, Inc., a clinical-stage biopharma company focused on immuno-oncology, are pleased to ann...
12.07.2023Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in GermanyST. LOUIS, MISSOURI, July 12, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the recruitment and the dosing of its f...
31.05.2023Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in the United KingdomSAINT LOUIS, MISSOURI, AND BERN SWITZERLAND, May 31, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the recruitment ...
16.05.2023Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S.ST. LOUIS, MISSOURI, USA, May 16, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel innate immune stimulating drugs with antigen depot properties, has announc...
24.01.2023Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor IndicationsSAINT LOUIS, MISSOURI, USA, January 24, 2023 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the initiation of recruitmen...
25.10.2022Immunophotonics Co-Founder Wei Chen, Ph.D. Awarded $2.5 Million Grant by the National Cancer InstituteSAINT LOUIS, MISSOURI, USA, October 25, 2022 /EINPresswire.com/ -- Immunophotonics, Inc. announced today that Wei Chen, Ph.D., co-founder and director of Immunophotonics, Inc. and Professor and Stephenson Chair of Biomedical Engineering, in...
10.05.2022Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indicationsST. LOUIS, MISSOURI AND BERN, SWITZERLAND, May 10, 2022 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious disea...
13.04.2022Immunophotonics Announces Appointment of Miguel Zubizarreta to Its Board of DirectorsST. LOUIS, MISSOURI, USA, April 13, 2022 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious disease, has strengt...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In